Recent reviews highlight that inhibitors of LDHA or MCT1/MCT4 not only reduce tumour-cell growth but also “trap” the immunosuppressive tumour-microenvironment (TME) and enhance immunotherapy efficacy (244). The gene discussed is LDHA; the disease is neoplasm.